false 0001442836 0001442836 2024-06-11 2024-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 11, 2024

 

 

 

MERSANA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware     001-38129     04-3562403  
(State or other jurisdiction
of incorporation) 		 

(Commission

File Number)  

  

(IRS Employer

Identification No.)  

 

840 Memorial Drive
Cambridge, Massachusetts		   02139

(Address of Principal Executive Offices)

   (Zip Code)  

 

Registrant’s telephone number, including area code: (617) 498-0020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.0001 par value MRSN The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On June 11, 2024, Mersana Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. At the Annual Meeting, the stockholders of the Company voted on the following three proposals: (1) to elect two Class I directors to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successors have been duly elected and qualified (“Proposal 1”), (2) to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Company’s definitive proxy statement on Schedule 14A filed by the Company with the U.S. Securities and Exchange Commission on April 26, 2024 (“Proposal 2”) and (3) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal 3”). The final results of the voting on each proposal are set forth below.

 

Proposal 1 - Election of Directors

 

The Company’s stockholders elected the two persons listed below as Class I directors, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The votes cast were as follows:

 

Nominees  For  Against  Abstain  Broker Non-Votes
Willard H. Dere, M.D.  84,576,414  12,733,786  104,329  8,260,872
Martin Huber, M.D.  96,836,592  472,410  105,527  8,260,872

 

Proposal 2 – Advisory Vote on Executive Compensation

 

The Company’s stockholders approved Proposal 2. The votes cast were as follows:

 

For  Against  Abstain  Broker Non-Votes
96,316,340  984,371  113,818  8,260,872

 

Proposal 3 – Ratification of Selection of Independent Registered Public Accounting Firm

 

The Company’s stockholders approved Proposal 3. The votes cast were as follows:

 

For  Against  Abstain
105,233,670  323,020  118,711 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  MERSANA THERAPEUTICS, INC.
     
Date: June 11, 2024 By: /s/ Alejandra Carvajal
    Alejandra Carvajal
    Senior Vice President, Chief Legal Officer and Secretary

 

 

 

 

v3.24.1.1.u2
Cover
Jun. 11, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 11, 2024
Entity File Number 001-38129
Entity Registrant Name MERSANA THERAPEUTICS, INC.
Entity Central Index Key 0001442836
Entity Tax Identification Number 04-3562403
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 840 Memorial Drive
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code 617
Local Phone Number 498-0020
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value
Trading Symbol MRSN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Mersana Therapeutics (NASDAQ:MRSN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Mersana Therapeutics.
Mersana Therapeutics (NASDAQ:MRSN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Mersana Therapeutics.